

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)  
June 19, 2025**

**NEOGENOMICS, INC.**

(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction  
of incorporation)

001-35756  
(Commission  
File Number)

74-2897368  
(I.R.S. Employer  
Identification No.)

9490 NeoGenomics Way, Fort Myers, Florida  
(Address of principal executive offices)

33912  
(Zip Code)

(239) 768-0600

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, par value \$0.001 per share

Trading Symbol(s):

NEO

Name of each exchange on which registered:

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02**                      **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 19, 2025, the Board of Directors of NeoGenomics, Inc. (the "Company") increased the size of the Board of Directors (the "Board") from nine to ten members and appointed Marjorie C. Green as a director to fill the vacancy resulting from that increase.

Ms. Green will serve as a member of the Board until the 2026 annual meeting of stockholders of the Company or until her resignation or removal and otherwise until her successor is elected. Ms. Green will receive compensation for their service as independent directors consistent with the Company's director compensation program previously disclosed in the Company's definitive proxy statement for its 2025 annual meeting of stockholders.

**Item 7.01**                      **Regulation FD Disclosure**

On June 24, 2025, the Company issued a press release regarding the foregoing, which is attached to the Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01**                      **Financial Statements and Exhibits.**

- (a) Not applicable
- (b) Not applicable
- (c) Not applicable
- (d) Exhibits.

99.1	<a href="#">Press Release of NeoGenomics, Inc. dated June 24, 2025</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### NEOGENOMICS, INC.

Date: June 24, 2025

By: /s/ Alicia C. Olivo  
Alicia C. Olivo  
EVP, General Counsel & Business Development  
and Corporate Secretary

### NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

**FORT MYERS, Fla., June 24, 2025—NeoGenomics, Inc. (NASDAQ: NEO)**, a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck.

Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue and pipeline investment.

"We are thrilled to welcome Marjorie to the NeoGenomics Board," said Lynn Tetrault, Chair of the Board of NeoGenomics. "Dr. Green's deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be invaluable as we continue to accelerate innovation into the precision oncology market."

Prior to joining Merck, Dr. Green served as Senior Vice President and Head of Late-Stage Development at Seagen. Prior to that, Dr. Green was Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech. She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center.

"I am honored to join NeoGenomics' Board at such an exciting time in the company's journey," said Dr. Marjorie Green. "Neo's unique oncology diagnostics offerings are well positioned for growth, and I look forward to contributing to the company's mission of improving patient care."

#### About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

#### Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its

---

ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at [www.sec.gov](http://www.sec.gov), for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

**Investor Contact**

Kendra Sweeney  
[ir@neogenomics.com](mailto:ir@neogenomics.com)

**Media Contact**

Andrea Sampson  
[asampson@sampsonprgroup.com](mailto:asampson@sampsonprgroup.com)